Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.48 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.48 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360402 | 0.85 | CYP1A2 (0.74) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6355943 | 0.84 | CYP1A2 (0.72) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL9015483 | 0.79 | MEN1 (0.66) | CYP1A2MEN1KMT2AALOX15 | |
| Vigabatrin SCHEMBL9063519 | 0.79 | MEN1 (0.62) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6361037 | 0.77 | CYP1A2 (0.62) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL6361052 | 0.77 | MEN1 (0.62) | CYP1A2MEN1KMT2AALOX15 | |
| SCHEMBL3844181 | 0.76 | CYP1A2 (0.61) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL1560660 | 0.74 | MEN1 (0.59) | CYP1A2MEN1KMT2ATSHRLMNA | |
| SCHEMBL9417101 | 0.74 | CYP1A2 (0.59) | CYP1A2MEN1KMT2AGABBR2GABBR1 | |
| SCHEMBL2353070 | 0.73 | CYP1A2 (0.57) | CYP1A2MEN1KMT2AGABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118662642-A | Gamma-aminobutyric acid receptor antagonist composition and application thereof in preparation of medicines for treating gastric cancer | 威海市立医院 | 2024-09-20 | — | — | CN | claimed |
| CN-117257815-A | New application of CGP35348 in preparation of antidepressant drugs | 中国人民解放军军事科学院军事医学研究院 | 2023-12-22 | — | — | CN | claimed |
| CN-117045803-A | Gamma-aminobutyric acid receptor antagonist composition and application thereof in preparation of medicines for treating gastric cancer | 威海市立医院 | 2023-11-14 | — | — | CN | claimed |
| WO-2014065606-A1 | AGENT FOR TREATING NERVE DISEASE, COMPRISING OSMOTIN COMPOSITION AND INHIBITOR FOR INHIBITING EXPRESSION OR ACTIVITY OF GABA B RECEPTOR PROTEINS | 경상대학교 산학협력단 (KR) | 2014-05-01 | — | — | WO | claimed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | claimed |
| EP-0701438-B1 | GABA-ERGIC MODULATION OF EYE GROWTH | UNIV PENNSYLVANIA (US) | 1999-07-07 | — | — | EP | claimed |
| US-5545631-A | GAMMA-AMINOBUTYRIC ACID ANTAGONIST; TREATS PETIT-MAL TYPE EPILEPSIES | CIBA-GEIGY CORPORATION (US) | 1996-08-13 | — | — | US | claimed |
| EP-0463560-B1 | New antiepileptic agents | CIBA GEIGY AG (CH) | 1995-10-25 | — | — | EP | claimed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | claimed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | claimed |
| EP-0463560-A1 | New antiepileptic agents | CIBA-GEIGY AG (CH) | 1992-01-02 | — | — | EP | claimed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | claimed |
| US-20250018061-A1 | GENE THERAPY IN SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY (SSADHD) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-16 | — | — | US | disclosed |
| CN-118662642-A | Gamma-aminobutyric acid receptor antagonist composition and application thereof in preparation of medicines for treating gastric cancer | 威海市立医院 | 2024-09-20 | — | — | CN | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0319479-A2 | Substituted propane-phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| EP-0319482-A2 | Novel substituted propane phosphinic acid compounds | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | CRH, BDNF, CHAT | CYP1A2 3291/4885MEN1 3754/4885KMT2A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.